<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Gastrointestinal neuroendocrine tumour &#8211; European Clinical Trials Information Network</title>
	<atom:link href="https://clinicaltrials.eu/meddra_pt/gastrointestinal-neuroendocrine-tumour/feed/" rel="self" type="application/rss+xml" />
	<link>https://clinicaltrials.eu</link>
	<description>Bridging Patients with Clinical Trials</description>
	<lastBuildDate>Fri, 12 Jun 2026 11:14:46 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png</url>
	<title>Gastrointestinal neuroendocrine tumour &#8211; European Clinical Trials Information Network</title>
	<link>https://clinicaltrials.eu</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Study of Lutetium-177 and Yttrium-90 DOTATATE combination therapy for patients with inoperable gastrointestinal neuroendocrine tumors</title>
		<link>https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-dotatate-lutetium-lu-177-and-yttrium-90-for-treating-gastrointestinal-neuroendocrine-tumors-in-patients-with-unresectable-tumors/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 29 Apr 2026 15:03:30 +0000</pubDate>
				<guid isPermaLink="false">https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-dotatate-lutetium-lu-177-and-yttrium-90-for-treating-gastrointestinal-neuroendocrine-tumors-in-patients-with-unresectable-tumors/</guid>

					<description><![CDATA[This clinical trial focuses on treating patients with neuroendocrine tumors of the gastrointestinal tract using a combination therapy called DuoNEN. The treatment consists of two radioactive substances: Lutetium-177 and Yttrium-90, which are combined with a special molecule called DOTATATE. These substances are designed to target and treat tumors that cannot be removed by surgery. The [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>This clinical trial focuses on treating patients with <b>neuroendocrine tumors</b> of the gastrointestinal tract using a combination therapy called DuoNEN. The treatment consists of two radioactive substances: <b>Lutetium-177</b> and <b>Yttrium-90</b>, which are combined with a special molecule called <b>DOTATATE</b>. These substances are designed to target and treat tumors that cannot be removed by surgery.</p>
<p>The purpose of this study is to develop a personalized treatment approach for patients with <b>gastroenteropancreatic neuroendocrine tumors</b> (GEP-NETs) using a mixture of radioactive medications. The treatment will be administered through <b>injection</b>, and patients will receive carefully calculated doses of the medication based on their individual needs.</p>
<p>During the study, participants will receive the combination therapy and undergo regular medical examinations. The treatment effectiveness will be monitored through various imaging tests, including <b>CT</b> (computed tomography) or <b>MRI</b> (magnetic resonance imaging) scans. Regular blood tests will also be performed to ensure patient safety throughout the treatment period.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
